On September 27, 2023, Tianjin Municipal Bureau of Science and Technology arranged for a panel of experts to visit Tianjin R&D Center of KeChow Pharma for the on-site evaluation of its experimental animal room. 

During the visit, the experts reviewed our application report and thoroughly examined all relevant information, documents, and environmental testing reports related to the application for the Laboratory Animal Use Certificate. They conducted a comprehensive inspection of our facilities and assessed them against national and Tianjin policies, regulations, and standards for the management of experimental animals. The experts commended our SPF-level experimental animal system facilities, laboratory management systems, standard operating procedures, and other resources. As a result, we successfully passed the comprehensive project evaluation and received the Laboratory Animal Use License on October 3, 2023 (License No.: SYXK (Jin) 2023-0007). 

About KeChow Pharma

KeChow Pharma is dedicated to developing innovative treatments for tumors, free radical-related diseases, and other therapeutic areas. Its pipeline includes MEK inhibitor, chemoprotective agents, KRASG12C inhibitor, pan-RAF inhibitor, and multiple other tumor-targeted inhibitors. Notably, its MEK inhibitor, Tunlametinib (HL-085), has submitted a new drug application in China and is included in the CSCO guidelines. Another novel drug, a chemoprotective agent, demonstrates superior efficacy and safety compared to current clinical counterparts. All research efforts aim to address unmet clinical needs globally and within China by developing original small molecule drugs with “best-in-class” potential, bridging domestic gaps and fulfilling scientific aspirations to enhance quality of life.